📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-24 18:23
10 analysed today
10
Today
133,648
All-time analysed
40,136
Positive
6,284
Negative
79,406
Neutral
7,754
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
22 announcements match the current filters (relevance ≥ 5).
Q1 FY27 Revenue Rises 15% to ₹304 Cr, EBITDA Reaches ₹25 Cr on Post-Merger Restatement
Orchid Pharma released its Q1 FY27 earnings call transcript following the completion of its merger with Dhanuka Laboratories. On a restated combined basis, Q1 FY27 revenue grew 15% YoY to ₹304 Cr (compared to ₹263 Cr in Q1 FY26), with EBITDA increasing to ₹25 Cr from ₹10 Cr. Gross margin improved 300 bps YoY to 33%. Strategic projects remain on track, including Cefiderocol commissioning targeted for December 2026 and the 7-ACA fermentation project aimed for March 2027 commercial batches.
Confidence: HIGH
What changedFiling of the Q1 FY27 investor concall transcript, presenting financials on a restated combined basis post-Dhanuka Laboratories merger.
Why it mattersDemonstrates operational turnaround after a challenging FY26 in cephalosporins, margin expansion from 30% to 33%, and critical timeline updates on key pipeline drivers (Exblifep, Cefiderocol, and 7-ACA).
Q1 FY27 Revenue: INR 304 croresQ1 FY27 EBITDA: INR 25 croresQ1 FY27 Gross Margin: 33%Russia Exblifep Deal Est. Value: USD 178 million7-ACA Target Commissioning: March 2027
📅 Short termPerformance shows early signs of recovery from price erosion and industry-wide cephalosporin overcapacity seen in FY26.
📈 Long termBackward integration into 7-ACA and geographic rollouts of Exblifep and Cefiderocol remain structural multi-year earnings drivers if successfully commissioned and commercialized.
⚠ Risk flags
- Persistent industry-wide overcapacities in generic cephalosporins exerting pricing pressure
- Execution and validation risks for complex fermentation at the 7-ACA facility
- Regulatory approval timelines from DCGI for new launches
Key Highlights
Combined Q1 FY27 revenue reached ₹304 Cr, up ~15% YoY from ₹263 Cr in Q1 FY26
Q1 FY27 EBITDA expanded to ₹25 Cr compared to ₹10 Cr in Q1 FY26
Exblifep 10-year licensing arrangement in Russia estimated at ~$178 million long-term value
7-ACA fermentation project targeted for commissioning and first commercial batch by March 2027
Cefiderocol project on schedule for commissioning by December 2026, followed by validation in Q4 FY27
👀 What to Watch
Track DCGI approval and commercial rollout for Cefiderocol in early 2027, along with execution progress and commercial batch deliveries for the backward-integrated 7-ACA fermentation facility by March 2027.
Orchid Pharma Reports Q1 FY27 Consolidated PAT of ₹3.22 Cr vs Loss YoY; DLL Merger Effective
Orchid Pharma released its Q1 FY27 investor presentation, reporting a turnaround to a consolidated net profit of ₹3.22 Cr compared to a net loss of ₹5.69 Cr in Q1 FY26. On a standalone basis, PAT reached ₹11.94 Cr compared to a net loss of ₹2.41 Cr in the prior year period. The presentation also highlights the completion of Dhanuka Laboratories Ltd's (DLL) amalgamation into Orchid Pharma under an NCLT-sanctioned scheme, effective July 10, 2026 (appointed date April 1, 2024).
Confidence: HIGH
What changedOrchid Pharma swung to consolidated profitability in Q1 FY27 and formalized the operational integration of Dhanuka Laboratories Ltd.
Why it mattersThe combination creates an integrated cephalosporin and anti-infectives platform with expanded API and formulation capabilities, supporting long-term margin recovery.
Consolidated PAT (Q1 FY27): ₹3.22 crConsolidated PAT (Q1 FY26): ₹-5.69 crStandalone PAT (Q1 FY27): ₹11.94 crMerger Effective Date: 10 July 2026
📅 Short termTurnaround in quarterly profitability and operational clarity post-merger should provide sentiment support.
📈 Long termThe combined entity creates an end-to-end cephalosporin manufacturing platform, but structural valuation re-rating hinges on scaling regulated market approvals and NCE out-licensing revenue.
⚠ Risk flags
- Pricing pressures in generic cephalosporin segments
- Post-merger integration risks across manufacturing facilities
Key Highlights
Q1 FY27 consolidated PAT turned positive to ₹3.22 Cr from a net loss of ₹5.69 Cr in Q1 FY26.
Standalone profit before tax stood at ₹11.94 Cr in Q1 FY27 compared to a loss of ₹2.41 Cr in Q1 FY26.
Consolidated basic and diluted EPS improved to ₹0.54 in Q1 FY27 from ₹-0.95 in Q1 FY26.
Merger of Dhanuka Laboratories Ltd into Orchid Pharma became effective on July 10, 2026 (appointed date April 1, 2024).
👀 What to Watch
Track the integration synergies from the Dhanuka Laboratories amalgamation and margin trajectory from key product rollouts (such as Exblifep and Cefiderocol).
Orchid Pharma Revises FY26 Financials Post Dhanuka Labs Merger; Consolidated PAT at Rs 9.96 Cr
Orchid Pharma submitted revised audited standalone and consolidated financial results for FY26 to incorporate the NCLT-sanctioned amalgamation of Dhanuka Laboratories Limited (effective July 10, 2026, with appointed date April 1, 2024). On a revised consolidated basis, FY26 revenue from operations stood at Rs 1,232.78 cr (down from Rs 1,397.61 cr in FY25), and full-year net profit was Rs 9.96 cr compared to Rs 135.07 cr in FY25. For Q4 FY26, revised consolidated revenue stood at Rs 368.33 cr with net profit of Rs 25.84 cr. Statutory auditors issued a routine qualified opinion concerning the unaudited financial statements of three US subsidiaries holding Rs 3.86 cr in total assets.
Confidence: HIGH
What changedOrchid Pharma restated its standalone and consolidated FY26 and comparative financials under Ind AS 103 following the formal NCLT approval of its merger with Dhanuka Laboratories.
Why it mattersThe restatement establishes the combined financial baseline for the merged entity, consolidating operational assets and resetting net worth to Rs 1,564.31 cr.
Revised FY26 Consolidated Revenue: Rs 1,23,277.84 lakhsRevised FY26 Consolidated PAT: Rs 995.91 lakhsRevised Q4 FY26 PAT: Rs 2,583.94 lakhsRevised Consolidated Net Worth: Rs 1,56,430.70 lakhsMerger Effective Date: July 10, 2026
📅 Short termNeutral; the market will adjust historical models to the restated figures reflecting the Dhanuka amalgamation.
📈 Long termThe consolidated structure may provide operational synergies and backward integration support for the company's core cephalosporin portfolio.
⚠ Risk flags
- Repetitive audit qualification regarding three unaudited US subsidiaries holding Rs 385.59 lakhs of assets
- Sharp drop in FY26 consolidated PAT to Rs 9.96 cr compared to Rs 135.07 cr in FY25
Key Highlights
Revised consolidated FY26 revenue from operations reported at Rs 1,23,277.84 lakhs (Rs 1,232.78 cr) vs Rs 1,39,761.17 lakhs in FY25
Revised FY26 consolidated PAT recorded at Rs 995.91 lakhs (Rs 9.96 cr), yielding revised diluted EPS of Rs 1.66
Q4 FY26 revised consolidated net profit reported at Rs 2,583.94 lakhs on total income of Rs 37,610.08 lakhs
Amalgamation with Dhanuka Laboratories took effect from July 10, 2026, with an appointed date of April 01, 2024
Consolidated net worth as of March 31, 2026 restated at Rs 1,56,430.70 lakhs (Rs 1,564.31 cr)
👀 What to Watch
Track subsequent quarterly filings to evaluate margin integration benefits from Dhanuka Laboratories alongside progress on sterile API expansions and Enmetazobactam out-licensing.
Q1 FY27 Net Profit at ₹3.22 Cr (vs ₹5.69 Cr YoY Loss); Revenue Up 15.6% to ₹304.17 Cr
Orchid Pharma reported consolidated revenue from operations of ₹304.17 crore for Q1 FY27, up 15.57% YoY from ₹263.19 crore, but down 17.42% QoQ from ₹368.33 crore. Consolidated net profit swung to ₹3.22 crore compared to a net loss of ₹5.69 crore in Q1 FY26, though lower than ₹25.84 crore recorded in Q4 FY26. Standalone profit was higher at ₹11.94 crore, reflecting subsidiary-level drag. Out of the ₹391.80 crore net proceeds raised via QIP, the company has deployed ₹97.62 crore towards the Jammu manufacturing facility under subsidiary OBPL.
Confidence: HIGH
What changedOrchid Pharma published its Q1 FY27 financial results, marking a turnaround to net profitability YoY despite seasonal sequential moderation.
Why it mattersConfirms operational turnaround and YoY top-line growth under Dhanuka management, though subsidiary-level expenses continue to weigh on consolidated profitability relative to standalone performance.
Consolidated Revenue (Q1 FY27): ₹30,417.13 lakhsConsolidated Net Profit (Q1 FY27): ₹322.44 lakhsConsolidated Basic EPS: ₹0.54Jammu Facility QIP Spend: ₹9,762 lakhs
📅 Short termMarket sentiment may be supported by the YoY return to profitability, balanced against a sequential decline compared to Q4 FY26.
📈 Long termValue creation depends on scaling high-margin formulations, commercializing new pipeline molecules, and operationalizing the Jammu API/intermediate capacity.
⚠ Risk flags
- Sequential earnings volatility with sharp PAT contraction from Q4 FY26 (₹25.84 Cr to ₹3.22 Cr)
- Losses in overseas/operating subsidiaries muting consolidated results relative to standalone
Key Highlights
Consolidated revenue from operations rose 15.57% YoY to ₹304.17 crore (₹30,417.13 lakhs)
Consolidated PAT turned around to ₹3.22 crore (₹322.44 lakhs) from a net loss of ₹5.69 crore in Q1 FY26
Standalone net profit stood at ₹11.94 crore (₹1,193.72 lakhs) versus a loss of ₹2.41 crore in Q1 FY26
QIP fund utilisation: ₹97.62 crore deployed out of ₹135 crore allocated for the OBPL Jammu manufacturing facility
👀 What to Watch
Monitor margin stabilization and commercial rollout traction of NCE Enmetazobactam (Exblifep) alongside the completion timeline of the Jammu facility.
4.45 Cr shares allotted to Dhanuka Laboratories shareholders in merger
Orchid Pharma has completed the allotment of 4,45,86,052 equity shares to the shareholders of Dhanuka Laboratories Limited as part of a Scheme of Amalgamation. This follows the scheme becoming effective on July 10, 2026, and the record date of July 23, 2026. The total paid-up share capital of the company has now increased to Rs. 59.88 crore, comprising 5,98,85,200 shares of Rs. 10 each. This allotment includes the cancellation of cross-holdings between the two entities.
Confidence: HIGH
What changedThe company has finalized the issuance of shares for the merger with Dhanuka Laboratories, resulting in a significant change in the total outstanding share count.
Why it mattersThis represents the final execution stage of the corporate restructuring with its parent group, simplifying the ownership structure but also leading to equity dilution for existing minority shareholders.
Shares Allotted: 4,45,86,052Post-Allotment Total Shares: 5,98,85,200Post-Allotment Paid-up Capital: Rs. 59,88,52,000Face Value per Share: Rs. 10
📅 Short termThe stock may experience volatility as the new shares are listed and the market adjusts to the revised equity base and potential changes in float.
📈 Long termThe merger integrates the Dhanuka Group's laboratory operations, which could lead to operational synergies and a more streamlined balance sheet over the coming years.
⚠ Risk flags
- Equity dilution for existing shareholders
- Integration risks associated with the amalgamation
Key Highlights
Allotment of 4,45,86,052 fully paid-up equity shares of Rs. 10 each to Dhanuka Laboratories shareholders.
Post-allotment total paid-up share capital stands at 5,98,85,200 shares (Rs. 59.88 Cr).
The Scheme of Amalgamation became effective from July 10, 2026.
New shares will rank pari-passu with existing equity and are proposed for listing on NSE and BSE.
👀 What to Watch
Investors should monitor the listing date of the new shares and observe the impact on Earnings Per Share (EPS) in upcoming quarters due to the expanded equity base.
4.45 Cr shares allotted; Orchid Pharma completes merger with Dhanuka Laboratories
Orchid Pharma has approved the allotment of 4,45,86,052 equity shares to the shareholders of Dhanuka Laboratories Limited (DLL) following their merger. This issuance follows the scheme of amalgamation which became effective on July 10, 2026, and the subsequent cancellation of DLL's cross-holdings. The company's total paid-up share capital now stands at Rs 59.88 crore, divided into 5.98 crore shares. This structural change formalizes the integration of the parent entity into Orchid Pharma, simplifying the Dhanuka Group's holding structure.
Confidence: HIGH
What changedThe company has completed the issuance of shares to the shareholders of the amalgamating entity (Dhanuka Laboratories), finalizing the equity restructuring of the merger.
Why it mattersThis simplifies the corporate structure under the Dhanuka Group. While it increases the share count, it reflects the absorption of the parent entity's assets and liabilities into Orchid Pharma.
Shares Allotted: 4,45,86,052Post-Allotment Paid-up Capital: Rs 59.88 CrRecord Date: July 23, 2026Total Post-Merger Shares: 5,98,85,200
📅 Short termThe listing of a large volume of new shares may lead to temporary price volatility or liquidity adjustments in the stock.
📈 Long termThe merger consolidates the group's pharmaceutical interests; long-term value depends on the successful commercialization of NCE Enmetazobactam and margin expansion through backward integration.
⚠ Risk flags
- Equity overhang if non-promoter shareholders of the merged entity seek liquidity
- Integration of legacy liabilities from the amalgamating company
Key Highlights
Allotment of 4,45,86,052 fully paid-up equity shares of Rs 10 each to eligible DLL shareholders.
Post-allotment paid-up share capital increased to Rs 59,88,52,000.
Total number of equity shares post-merger stands at 5,98,85,200 units.
The record date for determining eligible shareholders was July 23, 2026.
The scheme of amalgamation was previously declared effective as of July 10, 2026.
👀 What to Watch
Watch for the listing and commencement of trading for the newly allotted shares on BSE and NSE, and monitor the updated promoter holding profile in the next quarterly filing.
Orchid Pharma Sets July 23 Record Date for Merger with Dhanuka Labs; 161:5 Share Exchange Ratio
Orchid Pharma has announced that the scheme of amalgamation with its promoter entity, Dhanuka Laboratories Limited (DLL), became effective on July 10, 2026. The company has fixed July 23, 2026, as the record date to determine DLL shareholders eligible for the issuance of 161 Orchid Pharma shares (₹10 face value) for every 5 DLL shares (₹100 face value). This merger simplifies the corporate structure and increases Orchid's authorized share capital to ₹164.51 crore. The appointed date for this merger is retrospectively set as April 1, 2024.
Confidence: HIGH
What changedThe merger of the promoter entity Dhanuka Laboratories into Orchid Pharma is now legally effective, leading to a consolidated corporate structure.
Why it mattersThis is a structural simplification following Orchid's acquisition by Dhanuka Laboratories under the CIRP process; it consolidates the promoter's holding directly into the listed entity.
Record Date: July 23, 2026Share Exchange Ratio: 161:5New Authorized Capital: ₹164.51 CrAppointed Date: April 1, 2024Market Cap: ₹5730 Cr
📅 Short termThe stock may see some volatility leading up to the record date as the market adjusts for the new share issuance and the dissolution of the promoter entity.
📈 Long termThe merger simplifies the holding structure, allowing management to focus on operational growth drivers like the NCE Enmetazobactam and capacity expansions.
⚠ Risk flags
- Equity dilution from new share issuance
- Retrospective appointed date (April 1, 2024) may require accounting adjustments
Key Highlights
Record date for the merger/hive-off fixed as July 23, 2026
Share exchange ratio set at 161 equity shares of Orchid Pharma for every 5 shares of Dhanuka Laboratories
Authorized share capital increased to ₹164.51 crore following the amalgamation
The scheme became effective on July 10, 2026, with an appointed date of April 1, 2024
Dhanuka Laboratories stands dissolved without being wound up
👀 What to Watch
Investors should monitor the issuance and listing of new shares post-record date and assess the impact on the total outstanding equity and EPS dilution.
Orchid Pharma Finalizes Amalgamation with Dhanuka Labs; Sets Record Date July 23, 2026
Orchid Pharma has announced the completion of the amalgamation of its promoter entity, Dhanuka Laboratories Limited (DLL), into itself effective July 10, 2026. The share exchange ratio is fixed at 161 equity shares of Orchid (₹10 face value) for every 5 shares of DLL (₹100 face value). Consequently, Orchid's authorized share capital has increased to ₹164.51 Cr. The record date for determining DLL shareholders eligible for the new shares is July 23, 2026.
Confidence: HIGH
What changedThe promoter entity, Dhanuka Laboratories Limited, has merged into Orchid Pharma, resulting in a simplified corporate structure and an increase in Orchid's authorized capital.
Why it mattersThis merger simplifies the group structure and aligns the promoter's interests directly with the listed entity. It also formalizes the integration of the entity that originally acquired Orchid Pharma under the insolvency process.
New Authorized Capital: ₹164.51 CrShare Exchange Ratio (OPL:DLL): 161:5Record Date: July 23, 2026Appointed Date: April 1, 2024
📅 Short termThe stock may see activity leading up to the July 23 record date as the market adjusts to the finalized merger terms and the impending issuance of new shares.
📈 Long termStructurally positive as it removes a layer of holding company and consolidates the business under one listed entity, potentially improving transparency and operational focus.
⚠ Risk flags
- Equity dilution for existing minority shareholders depending on the final number of shares issued to the promoter entity
Key Highlights
Share exchange ratio of 161 fully paid-up equity shares of Orchid Pharma for every 5 shares held in Dhanuka Laboratories
Authorized share capital increased to ₹164.51 Cr, comprising 16.45 Cr equity shares of ₹10 each
Record date for share allotment to Dhanuka Laboratories shareholders set for July 23, 2026
The scheme is effective from July 10, 2026, with a retroactive appointed date of April 1, 2024
Dhanuka Laboratories Limited stands dissolved without being wound up following the merger
👀 What to Watch
Investors should monitor the change in the total outstanding share count and the final promoter holding percentage post-allotment. The retroactive appointed date of April 1, 2024, implies that upcoming financial statements will reflect the consolidated entity's performance.
Orchid Pharma Amalgamation Effective; 161:5 Share Exchange Ratio Set for July 23 Record Date
Orchid Pharma has announced that its scheme of amalgamation with Dhanuka Laboratories Limited (DLL) became effective on July 10, 2026. The company has fixed July 23, 2026, as the record date for the issuance of 161 equity shares of Orchid Pharma (₹10 face value) for every 5 shares of DLL (₹100 face value). This merger, with a retrospective appointed date of April 1, 2024, results in the dissolution of DLL and an increase in Orchid's authorized share capital to ₹164.51 Cr. The move simplifies the corporate structure by merging the promoter entity into the listed operating company.
Confidence: HIGH
What changedDhanuka Laboratories Limited (the promoter entity) has merged into Orchid Pharma Limited, making Orchid the primary surviving entity.
Why it mattersThis restructuring simplifies the group's holding structure and eliminates the intermediate promoter holding company, which is a standard corporate governance improvement following a CIRP acquisition.
Share Exchange Ratio: 161:5New Authorized Capital: ₹164.51 CrRecord Date: July 23, 2026Appointed Date: April 1, 2024Market Cap: ₹5730 Cr
📅 Short termThe stock may experience minor volatility leading up to the July 23 record date as the market adjusts to the finalized merger terms and share issuance.
📈 Long termThe merger simplifies the corporate structure; however, long-term value remains tied to the successful commercialization of new products like Enmetazobactam and margin improvement from backward integration.
⚠ Risk flags
- Potential equity dilution depending on the final number of shares issued to DLL shareholders
- Integration of any legacy liabilities from the amalgamating company
Key Highlights
Share exchange ratio fixed at 161 Orchid shares for every 5 DLL shares held.
Record date for determining eligible DLL shareholders set for July 23, 2026.
Authorized share capital increased to ₹164.51 Cr, divided into 16.45 Cr equity shares.
The scheme is effective from July 10, 2026, with an appointed date of April 1, 2024.
Dhanuka Laboratories Limited stands dissolved without being wound up.
👀 What to Watch
Investors should monitor the share allotment process post-July 23 and observe the updated shareholding pattern in the upcoming quarterly disclosures to confirm the final promoter stake.
Orchid Pharma Completes Merger with Dhanuka Laboratories; Scheme Effective July 10, 2026
Orchid Pharma has announced that the Scheme of Amalgamation with its promoter entity, Dhanuka Laboratories Limited, has become effective as of July 10, 2026. This follows the filing of the certified NCLT Chennai order with the Registrar of Companies. The merger is retrospective with an appointed date of April 01, 2024. Consequently, Dhanuka Laboratories stands dissolved, simplifying the corporate structure of the Rs 5,730 Cr market cap company.
Confidence: HIGH
What changedThe promoter entity, Dhanuka Laboratories Limited, has officially merged into Orchid Pharma Limited, making Orchid the surviving entity.
Why it mattersThis simplifies the group structure and formalizes the integration of the parent company that originally rescued Orchid Pharma from insolvency. It may lead to operational synergies and a cleaner corporate profile for the listed entity.
Effective Date: July 10, 2026Appointed Date: April 01, 2024Promoter Holding: 69.84%TTM Revenue: Rs 812 Cr
📅 Short termThe completion of this long-pending regulatory milestone provides clarity and is likely to be viewed positively by the market in the coming weeks.
📈 Long termThe merger simplifies the corporate architecture and allows management to focus on its 12-15% growth target and expansion into regulated markets without inter-company complexities.
Key Highlights
Effective date of the amalgamation is July 10, 2026, following NCLT approval.
The Appointed Date for the merger is set retrospectively to April 01, 2024.
Dhanuka Laboratories Limited stands dissolved without being wound up as per the scheme.
The merger consolidates the promoter entity (69.84% holding) into the listed entity Orchid Pharma.
👀 What to Watch
Investors should monitor the next quarterly financial statement to observe the impact of the consolidated balance sheet and any changes in the equity share capital structure.
$178 Million Licensing Deal with Pharmasyntez for Exblifep® in Russia
Orchid Pharma has entered into an exclusive licensing and supply agreement with Pharmasyntez JSC to commercialize its New Chemical Entity (NCE), Exblifep®, in the Russian market. The agreement represents a potential revenue opportunity of approximately $178 million (approx. ₹1,477 cr) over a 10-year period. Orchid will supply the finished dosage form, leveraging Pharmasyntez's extensive hospital procurement network in Russia, which generated 50.5 billion rubles in 2025 revenue. The deal is subject to regulatory approval by the Russian Ministry of Health.
Confidence: HIGH
What changedOrchid has secured a major commercial partner for its flagship NCE in Russia, transitioning from development to international commercialization in a new geography.
Why it mattersThis deal provides a long-term, high-margin revenue stream that significantly diversifies Orchid's geographic footprint and validates its R&D capabilities in the NCE space.
Total Deal Opportunity: $178 millionAnnualized Deal vs TTM Revenue: ~18.2%Partner 2025 Revenue: 50.5 billion rublesTTM Revenue: ₹812 crAgreement Duration: 10 years
📅 Short termThe stock is likely to react positively to the scale of the deal, which represents a significant portion of the company's current annual turnover.
📈 Long termSuccessful commercialization of Exblifep® in multiple global markets could structurally re-rate the company from a generic API player to an NCE-driven specialty pharma firm.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Regulatory approval risk in Russia
- Geopolitical uncertainties affecting trade with Russia
- Execution risk in supply chain logistics
Key Highlights
$178 million total potential opportunity over the first 10 years of the agreement
Annualized deal value represents approximately 18.2% of Orchid's TTM revenue of ₹812 cr
Partner Pharmasyntez operates 8 manufacturing facilities with 2025 revenue of 50.5 billion rubles
Exblifep® is the first Indian-originated NCE to receive both USFDA and EMA approvals
Orchid will supply the finished dosage form, capturing higher value than API supply
👀 What to Watch
Watch for the regulatory approval timeline from the Ministry of Health of the Russian Federation and the subsequent commencement of commercial shipments to gauge immediate revenue impact.
NCLT Approves Merger of Dhanuka Laboratories with Orchid Pharma; Swap Ratio 161:5
The National Company Law Tribunal (NCLT), Chennai, has officially approved the Scheme of Amalgamation between Dhanuka Laboratories Limited and Orchid Pharma Limited. The merger, which has an appointed date of April 01, 2024, is part of a 2019 resolution plan to create a larger entity with a projected turnover of ₹1,400-1,500 crores. Under the approved swap ratio, 161 equity shares of Orchid Pharma will be issued for every 5 shares held in Dhanuka Laboratories. The scheme aims to achieve operational synergies and a stronger balance sheet to attract future investment.
Key Highlights
NCLT Chennai Bench pronounced the order allowing the merger petition on June 05, 2026.
Share swap ratio fixed at 161 equity shares of Orchid Pharma (FV ₹10) for every 5 shares of Dhanuka Laboratories (FV ₹100).
Combined entity targets a sales turnover of ₹1,400-1,500 crores and EBITDA of ₹200-250 crores.
The Appointed Date for the scheme is confirmed as April 01, 2024.
The merger is expected to eliminate inter-company transactions and reduce administrative costs through a streamlined group structure.
👀 What to Watch
Investors should maintain a positive outlook as the merger nears its effective date, which will significantly scale up the company's financials; monitor for the final filing with the Registrar of Companies to confirm the effective date.
NCLT Chennai Sanctions Merger of Dhanuka Laboratories with Orchid Pharma
Orchid Pharma Limited has received approval from the Hon’ble National Company Law Tribunal (NCLT), Chennai, for the Scheme of Amalgamation of Dhanuka Laboratories Limited with the company. The order, sanctioned on June 05, 2026, ensures that Dhanuka Laboratories will be transferred to and vested in Orchid Pharma on a going concern basis. This follows the initial merger petition process that was previously updated on March 18, 2026. The company is currently awaiting the formal written order from the NCLT to finalize the documentation.
Key Highlights
NCLT Chennai sanctioned the Scheme of Amalgamation on June 05, 2026.
Dhanuka Laboratories Limited to be merged into Orchid Pharma Limited as a going concern.
The approval follows the merger petition process initiated and updated as of March 18, 2026.
The company will submit the formal copy of the NCLT order once it is made available.
👀 What to Watch
Investors should view this as a major regulatory milestone that facilitates business consolidation; monitor for the effective date and integration updates.
Orchid Pharma Q4 FY26: EBITDA Grows to ₹42.3 Cr; FY26 Revenue at ₹811 Cr Amid Industry Recovery
Orchid Pharma reported a stable Q4 FY26 with revenue of ₹238 crores and EBITDA of ₹42.3 crores, signaling a recovery from a challenging pricing cycle in the antibiotic industry. For the full year FY26, revenue stood at ₹811 crores with an EBITDA of ₹101 crores, impacted by global pricing pressures and inventory devaluations. The company is pivoting towards an integrated model, including the 7ACA project (Q1 CY2027) and a new US sterile formulation strategy targeting a $1.2 billion market. Management expects the pending merger with Dhanuka Laboratories to provide a 1-2% EBITDA margin expansion through operational synergies.
Key Highlights
Q4 FY26 EBITDA rose to ₹42.3 crores from ₹40 crores YoY, despite a difficult year for the antibiotic sector.
The 7ACA fermentation project is on track for commissioning in Q1 CY2027 to ensure backward integration.
New US market strategy targets 5-6 sterile products addressing a $1.2 billion market opportunity over the next 5 years.
Exblifep sales in Europe showed a fourfold (4x) improvement over the previous quarter.
The AMS platform, while currently an ₹8 crore annual EBITDA drag, is viewed as a strategic entry point for high-value products like Cefiderocol.
👀 What to Watch
Investors should monitor the progress of the 7ACA project and the formal approval of the Dhanuka Laboratories merger, which are key catalysts for margin expansion. The shift towards the US sterile formulation market represents a significant long-term growth lever.
Orchid Pharma Q4 PAT Rises 7% to ₹30 Cr; FY26 Revenue Falls 12% Amid Strategic Transition
Orchid Pharma reported a stable Q4 FY26 with revenue of ₹238 Cr and a 7% YoY increase in PAT to ₹30 Cr, driven by margin expansion to 18%. However, the full-year FY26 performance was weaker, with revenue declining 12% to ₹811 Cr and PAT falling 58% to ₹45 Cr compared to FY25. The company is currently in a 'Platform Creation' phase, focusing on backward integration through a 1,000 MT 7-ACA plant and expanding its Finished Dosage Form (FDF) presence in the US market. Strategic investments include $20-25 Mn for Cefiderocol to address global antimicrobial resistance.
Key Highlights
Q4 FY26 EBITDA margin improved to 18% from 17% YoY, despite flat revenue growth of ₹238 Cr.
Full-year FY26 PAT declined significantly to ₹45 Cr from ₹106 Cr in the previous fiscal year.
Backward integration project for 7-ACA at Kathua targets 1,000 MT capacity, with 75% intended for captive use.
Committed $20-25 Mn investment for Cefiderocol, aiming for a capacity of 1 million vials.
Strategic roadmap includes launching 5-6 sterile products in the US market by 2030 to capture higher margins.
👀 What to Watch
Investors should monitor the timely execution of the 7-ACA backward integration and US FDF launches, which are critical for returning to FY25 profitability levels. The long-term thesis remains tied to the company's transition from a pure API player to an integrated 'Soil to Vial' platform with novel antibiotic royalties.
NCLT Dismisses DBS Bank's Claim Against Orchid Pharma for CIRP Lease Rent
The National Company Law Tribunal (NCLT), Chennai Bench, has dismissed an application filed by DBS Bank (formerly Lakshmi Vilas Bank) against Orchid Pharma. The bank was seeking payment for lease rent and Insolvency Resolution Process Costs incurred during the company's CIRP period. The order, pronounced on April 2, 2026, and made available on April 10, 2026, rules in favor of Orchid Pharma. The company has confirmed that this dismissal results in nil financial impact on its operations.
Key Highlights
NCLT Chennai Bench dismissed Interim Application IA(IBC)/784/CHE/2020 filed by DBS Bank.
The claim involved lease rent dues and Insolvency Resolution Process Costs during the CIRP period.
The order was officially made available on April 10, 2026, following a pronouncement on April 2, 2026.
Orchid Pharma confirmed that the dismissal of this claim has nil financial or operational impact.
👀 What to Watch
This is a positive development as it removes a legacy legal hurdle and potential contingent liability from the company's insolvency period. Investors can view this as a sign of strengthening corporate clarity, though it does not change immediate earnings fundamentals.
CARE Ratings Downgrades Orchid Pharma's Long-Term Rating to 'BBB+'; Outlook Stable
CARE Ratings has downgraded Orchid Pharma's long-term bank facilities rating from 'CARE A-' to 'CARE BBB+' with a stable outlook. The rating agency also removed the company from 'Rating Watch with Developing Implications' following a review of its FY25 and 9MFY26 financial performance. While short-term ratings for facilities worth Rs. 84 crore were reaffirmed at 'CARE A2', the overall downgrade affects total bank facilities amounting to Rs. 366.50 crore. This revision reflects the agency's updated assessment of the company's credit profile and operational developments.
Key Highlights
Long-term bank facilities of Rs. 207.50 crore downgraded from CARE A- to CARE BBB+.
Short-term ratings for Rs. 84.00 crore reaffirmed at CARE A2.
Total bank facilities reviewed by CARE Ratings amount to Rs. 366.50 crore.
Company removed from 'Rating Watch with Developing Implications' and assigned a 'Stable' outlook.
Rating action based on FY25 audited and 9MFY26 provisional financial performance and pending NCLT orders.
👀 What to Watch
Investors should exercise caution as a credit downgrade typically indicates a perceived increase in credit risk or weakening financial metrics. Monitor the company's upcoming earnings reports to assess if operational cash flows are sufficient to service debt obligations.
Orchid Pharma Merger Update: NCLT Reserves Order for Amalgamation with Dhanuka Laboratories
Orchid Pharma Limited has announced that the National Company Law Tribunal (NCLT) has reserved its order for the Scheme of Amalgamation with Dhanuka Laboratories Limited as of March 18, 2026. This merger involves the integration of the promoter entity, Dhanuka Laboratories, into Orchid Pharma. The formal pronouncement of the order is the final step before the merger becomes effective. Investors are awaiting the specific details of the order to understand the impact on the company's capital structure.
Key Highlights
NCLT has reserved the final order for the merger of Dhanuka Laboratories with Orchid Pharma on March 18, 2026.
The amalgamation process is being carried out under Regulation 30 of SEBI Listing Regulations.
Dhanuka Laboratories is the Amalgamating Company, while Orchid Pharma is the Amalgamated Company.
The company will notify stock exchanges and shareholders once the formal written order is received.
👀 What to Watch
Investors should maintain a watch on the stock as the formal NCLT order pronouncement is imminent. The merger is a significant corporate restructuring that could impact the company's valuation and operational efficiency.
Orchid Pharma Q3 FY26: EBITDA Margins Contract to 6% Amid Global Antibiotic Pricing Pressure
Orchid Pharma reported a 5% YoY decline in Q3 revenue to INR 207 crores, with EBITDA margins dropping significantly from 17% to 6% due to global antibiotic pricing pressure. The 9-month performance reflects a 16% revenue decline and a 12% price erosion in the oral segment, alongside a 10% quantity erosion. Despite the weak core market, the company is seeing momentum in its differentiated product Exblifep, with successful launches in Spain, Italy, and the GCC region. The strategically critical 7ACA backward integration project remains on track for mechanical completion by September.
Key Highlights
Q3 revenue fell 5% YoY to INR 207 crores; 9-month EBITDA halved to INR 58 crores with margins at 10%.
Oral segment faced 12% price erosion and 10% quantity erosion on a 9-month basis due to global market stress.
Exblifep volumes grew over 200% sequentially in Europe (Spain and Italy) from a small base as commercialization ramps up.
Regulated market share dropped to 25% of total sales compared to the historical average of 33%.
7ACA project reached a milestone with all fermenters erected; mechanical completion targeted for September to enhance backward integration.
👀 What to Watch
Investors should monitor the ramp-up of high-margin products like Exblifep and the timely commissioning of the 7ACA plant to offset base business volatility. While the current earnings are weak, the long-term thesis depends on the successful transition to differentiated products and backward integration.
Orchid Pharma Q3 FY26 Sales Down 5%, EBITDA Plummets 65% with Net Loss of ₹6 Cr
Orchid Pharma reported a weak performance for Q3 FY26, with standalone sales declining 5% year-on-year to ₹207 crore. The company's EBITDA saw a significant drop of 65%, falling to ₹13 crore, primarily due to a sharp contraction in gross margins from 43% to 31%. Consequently, the company posted a net loss of ₹6 crore for the quarter compared to a profit of ₹24 crore in the same period last year. For the nine-month period, sales are down 16% and EBITDA has halved, indicating sustained operational pressure.
Key Highlights
Standalone sales for Q3 FY26 fell to ₹207 crore from ₹217 crore in Q3 FY25, a 5% decline.
EBITDA margins contracted sharply to 6% in Q3 FY26 from 17% in the previous year's quarter.
Reported a net loss (PBT/PAT) of ₹6 crore in Q3 FY26 against a profit of ₹24 crore in Q3 FY25.
Gross margins declined significantly to 31% compared to 43% in the year-ago period due to higher COGS.
9M FY26 performance shows a 16% decline in sales and a 50% drop in EBITDA compared to 9M FY25.
👀 What to Watch
Investors should exercise caution as the company faces significant margin pressure and declining sales. It is advisable to monitor the management's commentary regarding raw material costs and recovery timelines before making new positions.
